Ablynx raises EUR 41.7M in private placement

Antibody company Ablynx N.V. (Euronext:ABLX) raised EUR 41.7 million ($56.9 million) through the sale of 4.9 million shares at EUR 8.50 in a private placement to institutional investors. The price is a 7% discount to Ablynx's close of EUR 9.10 on Friday, before the company proposed to raise EUR 30 million ($41 million) in the offering. Jefferies; KBC Securities; and Kempen & Co. were joint bookrunners.

Ablynx said part of the proceeds will be used to support development of the company's caplacizumab ( anti-vWF Nanobody). Next year, Ablynx plans to start a Phase III trial of caplacizumab in thrombotic thrombocytopenic purpura ( TTP). The product comprises nanobodies targeting von Willebrand factor (vWF). ...